Cardiovascular morbidity and mortality in bipolar disorder

Annals of Clinical Psychiatry

Volumn 23, Issue 1, 2011, Pages 40-47

  Weiner, Miriam ^a   Warren, Lois ^a   Fiedorowicz, Jess G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Bipolar disorder; Cardiovascular disease; Hypertension; Metabolic syndrome; Mortality; Obesity

Indexed keywords

LITHIUM; NEUROLEPTIC AGENT; VALPROIC ACID; CARDIOVASCULAR AGENT; PSYCHOTROPIC AGENT;

BIPOLAR DISORDER; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; MENTAL HEALTH CARE; METABOLIC SYNDROME X; MORBIDITY; OBESITY; POPULATION RISK; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SMOKING HABIT; STANDARDIZED MORTALITY RATIO; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN; BEHAVIOR CONTROL; CAUSE OF DEATH; COMORBIDITY; EARLY DIAGNOSIS; LIFESTYLE; METHODOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY;

BEHAVIOR CONTROL; BIPOLAR DISORDER; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; EARLY DIAGNOSIS; HUMANS; LIFE STYLE; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; RISK ASSESSMENT;

EID: 79961116496     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Kraepelin E. Manic-depressive insanity and paranoia. Edinburgh, Scotland: E and S Livingstone; 1921.
2. Bell LV. On a form of disease resembling some advanced stages of mania and fever, but so contradistinguished from any ordinarily described combination of symptoms, as to render it probable that it may be overlooked and hitherto unrecorded malady. American Journal of Insanity. 1849;6:97-127.
3. Ray I. On undescribed forms of acute maniacal disease. American Journal of Insanity. 1853;10:95-111.
4. Derby IM. Manic-depressive "exhaustion" deaths: an analysis of "exhaustion" case histories. Psychiatr Q. 1933;7:436-449.
5. Adland ML. Review, case studies, therapy, and interpretation of the acute exhaustive psychoses. Psychiatr Q. 1947;21:38-69.
6. Slater E. Zur Erbpathoogie des manisch-depressiven Irreseins. Die Eltern und Kinder von Manisch-Depressiven. [Hereditary pathology of manic-depressive illness. Parents and offspring of manic-depressives]. Z Gesamte Neurol Psychiatr. 1938;163:1-47.
7. Bumke O. Handbuch der Geisteskrankheiten. Berlin, Germany: Julius Springer Verlag; 1928.
8. Alstrom CH. Mortality in mental hospitals. Acta Psychiatr Neurol. 1942;17:1-42.
9. Ødegard Ø. Mortality in Norwegian mental hospitals 1926-1941. Acta Genet Stat Med. 1951;2:141-173.
10. Malzberg B. Rates of discharge and rates of mortality among first admissions to the New York civil state hospitals. Ment Hyg. 1952;36:104-120.
11. Malzberg B. Rates of discharge and rates of mortality among first admissions to the New York civil state hospitals. II. Ment Hyg. 1952;36:618-638.
12. Malzberg BM. Rates of discharge and rates of mortality among first admissions to the New York Civil State Hospitals. III. Ment Hyg. 1953;37:619-654.
13. Babigian HM, Odoroff CL. The mortality experience of a population with psychiatric illness. Am J Psychiatry. 1969;126:470-480.
14. Merikangas KR, Kalaydjian A. Magnitude and impact of comorbidity of mental disorders from epidemiologic surveys. Curr Opin Psychiatry. 2007;20:353-358. (Pubitemid 46889662)
15. Berkson J. Limitations of the application of fourfold tables to hospital data. Biometrics Bulletin. 1946;2:47-53.
16. Tsuang MT, Woolson RF, Fleming JA. Causes of death in schizophrenia and manic-depression. Br J Psychiatry. 1980;136:239-242. (Pubitemid 10081823)
17. Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord. 1987;13:287-292. (Pubitemid 18049394)
18. Weeke A, Vaeth M. Excess mortality of bipolar and unipolar manic-depressive patients. J Affect Disord. 1986;11:227-234. (Pubitemid 17018802)
19. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord. 1994;31:91-96. (Pubitemid 24183896)
20. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167-181. (Pubitemid 34628324)
21. Laursen TM, Munk-Olsen T, Nordentoft M, et al. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68:899-907. (Pubitemid 47015490)
22. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-850. (Pubitemid 32979302)
23. Perris C, d'Elia G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. X. Mortality, suicide and life-cycles. Acta Psychiatr Scand Suppl. 1966;194:172-189.
24. Sims A, Prior P. The pattern of mortality in severe neuroses. Br J Psychiatry. 1978;133:299-305. (Pubitemid 8400671)
25. Kallner G, Lindelius R, Petterson U, et al. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry. 2000;33:8-13. (Pubitemid 30103940)
26. Müller-Oerlinghausen B, Wolf T, Ahrens B, et al. Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients. Acta Psychiatr Scand. 1994;90:295-297. (Pubitemid 24303599)
27. Zilber N, Schufman N, Lerner Y. Mortality among psychiatric patients-the groups at risk. Acta Psychiatr Scand. 1989;79:248-256. (Pubitemid 19087476)
28. Vestergaard P, Aagaard J. Five-year mortality in lithium- treated manic-depressive patients. J Affect Disord. 1991;21:33-38.
29. Tsai SY, Lee CH, Kuo CJ, et al. A retrospective analysis of risk and protective factors for natural death in bipolar disorder. J Clin Psychiatry. 2005;66:1586-1591. (Pubitemid 43068700)
30. Craig TJ, Ye Q, Bromet EJ. Mortality among first-admission patients with psychosis. Compr Psychiatry. 2006;47:246-251. (Pubitemid 43849685)
31. Black DW, Warrack G, Winokur G. The Iowa record-linkage study. III. Excess mortality among patients with 'functional' disorders. Arch Gen Psychiatry. 1985;42:82-88. (Pubitemid 15190214)
32. Meloni D, Miccinesi G, Bencini A, et al. Mortality among discharged psychiatric patients in Florence, Italy. Psychiatr Serv. 2006;57:1474-1481. (Pubitemid 44671659)
33. Rorsman B. Mortality among psychiatric patients. Acta Psychiatr Scand. 1974;50:354-375.
34. Martin RL, Cloninger CR, Guze SB, et al. Mortality in a follow-up of 500 psychiatric outpatients. II. Cause-specific mortality. Arch Gen Psychiatry. 1985;42:58-66. (Pubitemid 15190211)
35. Martin RL. Methodological and conceptual problems in the study of mortality in psychiatry. Psychiatr Dev. 1985;3:317-333.
36. Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand. 1976;53:139-147.
37. Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord. 2006;8:175-181. (Pubitemid 44026770)
38. Hermida OG, Fontela T, Ghiglione M, et al. Effect of lithium on plasma glucose, insulin and glucagon in normal and streptozotocin-diabetic rats: role of glucagon in the hyperglycaemic response. Br J Pharmacol. 1994;111:861-865. (Pubitemid 24151676)
39. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70:65-69. (Pubitemid 14065224)
40. Pylvänen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 2002;43:514-517. (Pubitemid 34533707)
41. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res. 2005;80:55-59.
42. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975-981. (Pubitemid 30412350)
43. Spivak B, Lamschtein C, Talmon Y, et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol. 1999;22:98-101.
44. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999;156:1270-1272. (Pubitemid 29374891)
45. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999;60:767-770.
46. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J Clin Psychiatry. 2006;67:1055-1061. (Pubitemid 44230876)
47. Lambert BL, Chou CH, Chang KY, et al. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf. 2005;14:417-425. (Pubitemid 40895550)
48. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed. 2004;6:5.
49. Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry. 2005;66:1463-1467. (Pubitemid 41779546)
50. Carlson C, Hornbuckle K, Delisle F, et al. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol. 2006;16:366-375. (Pubitemid 43815731)
51. Gianfrancesco F, White R, Wang RH, et al. Antipsychotic- induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328-335. (Pubitemid 36951173)
52. Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care. 2005;11(suppl): S235-S241. (Pubitemid 41361624)
53. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159:255-262. (Pubitemid 34126903)
54. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.
55. Kilbourne AM, Rofey DL, McCarthy JF, et al. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord. 2007;9:443-452. (Pubitemid 47202506)
56. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606-2610.
57. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207-213. (Pubitemid 34407079)
58. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7:424-430. (Pubitemid 41419409)
59. Shah A, Shen N, El-Mallakh RS. Weight gain occurs after onset of bipolar illness in overweight bipolar patients. Ann Clin Psychiatry. 2006;18:239-241. (Pubitemid 44949902)
60. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68:917-923. (Pubitemid 47015492)
61. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008;20:131-137. (Pubitemid 352009283)
62. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368-373. (Pubitemid 39345287)
63. Yates WR, Wallace R. Cardiovascular risk factors in affective disorder. J Affect Disord. 1987;12:129-134. (Pubitemid 17071787)
64. Johannessen L, Strudsholm U, Foldager L, et al. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. 2006;95:13-17. (Pubitemid 46110785)
65. Raphael T, Parsons JP. Blood sugar studies in dementia praecox and manic-depressive insanity. Arch Neurol Psychiatry. 1921;5:687-709.
66. Kasanin J. The blood sugar curve in mental disease: II. The schizophrenia (dementia praecox) groups. Arch Neurol Psychiatry. 1926;16:414-419.
67. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417-1420. (Pubitemid 29416540)
68. Brandrup E, Randrup A. A controlled investigation of plasma lipids in manic-depressives. Br J Psychiatry. 1967;113:987-992.
69. Cardenas J, Frye MA, Marusak SL, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106:91-97.
70. Garcia-Portilla MP, Saiz PA, Benabarre A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106:197-201. (Pubitemid 350309669)
71. van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008;10:342-348. (Pubitemid 351637699)
72. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health. 2006;2:14.
73. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr. 2007;29:330-336. (Pubitemid 351358057)
74. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007;98:247-252. (Pubitemid 46151723)
75. Kilbourne AM, Post EP, Bauer MS, et al. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord. 2007;102:145-151. (Pubitemid 47044893)
76. Kreyenbuhl J, Dickerson FB, Medoff DR, et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis. 2006;194:404-410.